Vericel

Vericel Corporation
Formerly	Aastrom Biosciences, Inc.
Company type	Public
Traded as	Nasdaq: VCEL; Russell 2000 component; S&P 600 component
Industry	Biotechnology
Founded	1989; 35 years ago in Ann Arbor, Michigan, United States
Headquarters	Cambridge, Massachusetts, United States
Number of locations	2
Key people	Nick Colangelo (CEO); Daniel Orlando (COO); Gerard Michel (CFO);
Products	MACI; Epicel; Carticel;

Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.^[1]

In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011.^[1] This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.^[1]

In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.^[1]

References

^ ^a ^b ^c ^d Seiffert, Don (21 Oct 2014). "In Vericel, an old Genzyme business gets new life and space in Cambridge". bioflash. Boston Bus. J.

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

[seiffert2014-1] Seiffert, Don (21 Oct 2014). "In Vericel, an old Genzyme business gets new life and space in Cambridge". bioflash. Boston Bus. J.

[1]